TrialResults-center.org
Search
Menu
Home
Search
Recent trials
Browse pathology
Browse treatment
About us
stent
systematic review
meta-analysis
network meta-analysis
Select
antiplatelets drug
antithrombotics
dual antiplatelet therapy
All type of patient
6 months DAPT
antiplatelet drugs
dual antiplatelet therapy
prolonged dual antiplatelet therapy
triple antiplatelet
cilostazol
clopidogrel
ticlopidine
vs anticoagulant + antiplatelet
vs antiplatelet drugs
vs short antiplatelet drug
vs standard clopidogrel
Filter
hide ongoing
show ongoing
hide ongoing
all ROB
Show all trials
Show only trial at low risk of bias
Hide exploratory trials
all results
Show all trials
Show only trial with conclusive result
Group by
Group by...
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
MA
in first
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in second
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in third
Description
Synopsis
Comparison
Treatments
Patients
Characteristics
Method
Risk of bias
References
None
Tools
Indexation
Results
Global trial result
Main results
All results
All result tag
NCT results
MACE (23)
All cause death (14)
stent thrombosis (14)
myocardial infarction (fatal and non fatal) (13)
stroke (fatal and non fatal) (12)
Major bleeding (11)
Cardiovascular death/MI/stent thrombosis (2)
GUSTO severe/moderate bleeding (2)
any bleedings (2)
Cardiovascular death (2)
Options
Numeric
bar chart
forest plot
medians
Trial
Studied trt
Control trt
patients
tags
ROB
Trial result
MACE
All cause death
antithrombotics
not classified
DECLARE-LONG II , 2011
-
EXCELLENT, 2011
NCT
6-month dual antiplatelet therapy
12 months dual antiplatelet
negative
76%
PRODIGY, 2011
NCT
24 months of dual antiplatelet treatment
6 months dual antiplatelet
negative
7%
0%
WOEST
NCT
triple therapy
dual antiplatelet therapy
-
RESET
NCT
Endeavor stent and three months of DAPT
standard 12-month DAPT and other DES
negative
60%
DES-LATE, 2010
NCT
prolonged dual antiplatelet therapy
12 months dual antiplatelet
Risk of bias
negative
65%
52%
ISAR-SAFE, 2009
NCT
12 months dual antiplatelet
6 months dual antiplatelet
Low risk of bias
-
CILON-T, 2010
triple antiplatelet
dual antiplatelet therapy
Exploratory
negative
-7%
-33%
cilostazol
Kunishima, 1997
cilostazol
aspirin
negative
-100%
Sekiya, 1998
cilostazol + aspirin
aspirin
negative
-100%
Yoon, 1999
cilostazol + aspirin
ticlopidine + aspirin
negative
-32%
Kamishirado, 2002
cilostazol + aspirin
ticlopidine + aspirin
negative
-100%
Kozuma, 2001
cilostazol + aspirin
ticlopidine + aspirin
negative
-100%
Ochiai, 1999
cilostazol + aspirin
ticlopidine + aspirin
negative
0%
Park, 1999
cilostazol + aspirin
ticlopidine + aspirin
negative
97%
clopidogrel
REAL-LATE, ZEST-LATE, 2010
NCT
clopidogrel+aspirin
aspirin
negative
52%
GRAVITAS, 2011
NCT
high-dose clopidogrel
normal-dose clopidogrel
Risk of bias
negative
-30%
Müller, 2000
clopidogrel + aspirin
ticlopidine + aspirin
negative
78%
CLASSICS, 2000
clopidogrel + aspirin
ticlopidine + aspirin
negative
31%
TOPPS, 2001
clopidogrel + aspirin
ticlopidine + aspirin
negative
-16%
Piamsomboon, 2001
clopidogrel + aspirin
ticlopidine + aspirin
negative
-100%
ticlopidine
STARS (vs aspirin), 1998
ticlopidine + aspirin
aspirin
suggesting
-85%
Hall, 1996
ticlopidine + aspirin
aspirin
negative
98%
FANTASTIC, 1998
ticlopidine + aspirin
coumadin + aspirin
negative
-30%
ISAR, 1996
ticlopidine + aspirin
coumadin + aspirin
suggesting
-75%
Foussas, 2000
ticlopidine + aspirin
coumadin + aspirin
suggesting
-69%
MATTIS, 1998
ticlopidine + aspirin
coumadin + aspirin
negative
-49%
STARS (vs coumadin+asp), 1998
ticlopidine + aspirin
coumadin + aspirin
suggesting
-80%
dual antiplatelet therapy
not classified
OPTIMIZE, 2013
NCT
3 months DAPT
12 months DAPT
Risk of bias
-
EXCELLENT, 2011
NCT
6-month dual antiplatelet therapy
12 months dual antiplatelet
negative
76%
PRODIGY, 2011
NCT
24 months of dual antiplatelet treatment
6 months dual antiplatelet
negative
7%
0%
RESET
NCT
Endeavor stent and three months of DAPT
standard 12-month DAPT and other DES
negative
60%
DES-LATE, 2010
NCT
prolonged dual antiplatelet therapy
12 months dual antiplatelet
Risk of bias
negative
65%
52%
ISAR-SAFE, 2009
NCT
12 months dual antiplatelet
6 months dual antiplatelet
Low risk of bias
-
clopidogrel
REAL-LATE, ZEST-LATE, 2010
NCT
clopidogrel+aspirin
aspirin
negative
52%
GRAVITAS, 2011
NCT
high-dose clopidogrel
normal-dose clopidogrel
Risk of bias
negative
-30%
×
Modal title